ASCENTAGE PHARMA GROUP INTERNATIONAL
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG): 23 pipeline candidates · 5 upcoming catalysts · ~29 mo cash runway · 25 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
28.8 months
D/E 8.55 · 0% dilution
Lead: Phase 2
23 candidates
5 upcoming, next in ~500d
N/A
A transparent, data-derived signal for ASCENTAGE PHARMA GROUP INTERNATIONALacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6B
Cash
$122.4M
Quarterly Burn
$15.3M
Runway
28.8 mo
Revenue
$134.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| [14c] lpm3770164 | Phase 1 |
| apg-115 | Phase 2 |
| apg-1252 | Phase 1 |
| apg-1387 | Phase 1/Phase 2 |
| apg-2449 | Phase 1 |
| apg-2575 | Phase 1 |
| apg-3288 | Phase 1 |
| apg-5918 | Phase 1 |
| apg2575 | Phase 1 |
| ascentage pharma hqp1351 bioavailable inhibitor | Phase 1 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$15K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 498 | $12K |
| eversource wealth advisors, llc | 95 | $3K |
| royal bank of canada | 6 | $0 |
Frequently asked questions
How many drug candidates are in ASCENTAGE PHARMA GROUP INTERNATIONAL's pipeline?
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ASCENTAGE PHARMA GROUP INTERNATIONAL's lead drug candidate?
ASCENTAGE PHARMA GROUP INTERNATIONAL's most advanced tracked candidate is [14c] lpm3770164 (Phase 1) for Huntington Disease.
What is ASCENTAGE PHARMA GROUP INTERNATIONAL's next catalyst?
ASCENTAGE PHARMA GROUP INTERNATIONAL's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) " — expected October 31, 2027.
What is ASCENTAGE PHARMA GROUP INTERNATIONAL's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ASCENTAGE PHARMA GROUP INTERNATIONAL has approximately 28.8 months of cash runway.
What is ASCENTAGE PHARMA GROUP INTERNATIONAL's market capitalization?
ASCENTAGE PHARMA GROUP INTERNATIONAL's market capitalization is approximately $1.6B.
Get the full picture on ASCENTAGE PHARMA GROUP INTERNATIONAL
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.